Method for treating checkpoint inhibitors induced adverse events
AssigneesAssistance Publique-Hopitaux de Paris, Sorbonne Universite, Institut National De La Sante Et De La Recherche Medicale (Inserm), Vanderbilt University
InventorsJoe-Elie Salem, Yves Allenbach, Mathieu Kerneis, Javid Moslehi, Douglas Johnson
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of CTLA4 agonist for treating or preventing adverse events in patient treated with an immune checkpoint inhibitor.
Claims21
A method for treating an adverse event induced by a treatment with an immune checkpoint inhibitor comprising administering an effective amount of abatacept to a patient in need thereof, wherein the adverse event is a de novo adverse event induced by the treatment with the immune checkpoint inhibitor, and not related to a preexisting immune condition in the patient treated with the immune checkpoint inhibitor.
A method for treating myocarditis induced by treatment with an immune checkpoint inhibitor, the method comprising administering an effective amount of abatacept to a patient in need thereof, wherein the adverse event is a de novo adverse event induced by the treatment with the immune checkpoint inhibitor, not related to a preexisting immune condition in the patient treated with the immune checkpoint inhibitor.
A method for preventing an adverse event induced by a treatment with an immune checkpoint inhibitor comprising administering an effective amount of abatacept to a patient in need thereof, wherein the adverse event is a de novo adverse event induced by the treatment with the immune checkpoint inhibitor, not related to a preexisting immune condition in the patient treated with the immune checkpoint inhibitor.
Dependencies are inferred from the claim text.